Karolinska Development divests its holdings in Xspray and receives SEK 12.5 million directly and additionally SEK 0.8 million via KCIF's sale
STOCKHOLM - October 27, 2017. Karolinska Development today announces that the company has sold its entire holdings in Xspray Pharma AB. Furthermore, KCIF Co-investment Fund KB is also selling its shares in the company. In total, the transactions generate SEK 13.3 million to Karolinska Development.
In September of 2015 Karolinska Development divested its holdings in Xspray to new owners. In conjunction with this, an earn-out agreement was signed which gave Karolinska Development and KCIF Co-Investment Fund KB, a holding company jointly owned by the European Investment Fund and Karolinska Development, the right to receive shares in Xspray should the company be listed in the future. Karolinska Development had the right to receive 462,155 shares directly and an additional 29,692 shares via KCIF corresponding to 3.74% of the company. Xspray was listed in September 2017, and Karolinska Development as well as KCIF have now divested their entire holdings for a total amount of SEK 13.3 million.
"Karolinska Development's sale of the shares in Xspray is an example of how our strategy with earn out-agreements can result in a good outcome. The liquidity from the sale will strengthen our cash position and will be well suited for future investments," says Viktor Drvota, CEO, Karolinska Development.
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: email@example.com
Christian Tange, CFO, Karolinska Development AB
Phone: +46 73 712 14 30, e-mail: firstname.lastname@example.org
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com
This information is information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Viktor Drvota, at 07:00 pm CEST on 27th of October 2017.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
SEMAFO Mourns Passing of Board Chairman Jean Lamarre23.11.2017 22:01 | Pressmeddelande
MONTREAL, Nov. 23, 2017 (GLOBE NEWSWIRE) -- SEMAFO (TSX:SMF) (OMX:SMF) announces with sadness the passing of Mr. Jean Lamarre, Chairman of the Board of Directors of the Corporation, on November 22, 2017 following a short illness. Mr. Lamarre joined the Corporation's Board of Directors in 1997 and was appointed Chairman of the Board in 2000, a position he held until his demise. "Jean made an indelible mark on SEMAFO, both in terms of his corporate governance expertise and his 45 years of experience in Africa," said President and CEO Benoit Desormeaux. "Over his 20-year tenure with SEMAFO, he brought unique insight, business acumen and leadership to the Corporation as it transitioned from an exploration company to a junior gold producer. He did this, always without compromising his values: the integrity of the Corporation, his deep love for Africa and its people, and his priority to SEMAFO's long-term sustainability. On behalf of SEMAFO's Board of Directors, management and employe
Premier to join industry leaders at BDA London forum23.11.2017 21:39 | Pressmeddelande
HAMILTON, Bermuda, Nov. 23, 2017 (GLOBE NEWSWIRE) -- Premier David Burt will join more than two-dozen Bermuda executives in a multi-industry forum being held in London next week to showcase the breadth of expertise and advantages offered by the island's global business market. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/78c5ac53-07f7-4dd8-83e0-753ea5b4c80b Organised by the Bermuda Business Development Agency (BDA), the one-day event Tuesday, November 28 at ME London has attracted over 200 registrants. It will feature top regulatory and industry leaders in moderated discussion panels covering re/insurance, captive insurance, insurance-linked securities, asset management, family offices, and trust and private-client business. A networking reception will wrap the event in the evening. "The government supports the Bermuda Business Development Agency in this awareness-raising event that offers such gre
Crown Bioscience and Data Sciences International (DSI) Partner to Advance Metabolic Disease Research Using an Implanted Telemetry Device for Long-Term Blood Glucose Monitoring23.11.2017 14:00 | Pressmeddelande
SANTA CLARA, Calif., Nov. 23, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation cardiovascular and metabolic disease research, announces the successful development of an enhanced method for preclinical obesity and type 2 diabetes studies in partnership with Data Sciences International (DSI). Crown Bioscience's clinically relevant models and DSI's HD-XG implantable glucose device combine to create a superior approach to preclinical metabolic disease research. Recently published work in the Journal of Endocrinological Investigation and Nature's Scientific Reports demonstrates the advantages of a new method using DSI's HD-XG implantable glucose device and Crown Bioscience's models of spontaneous and diet-induced diabetes. The HD-XG device allows for continuous, long-term measurement
LeoVegas AB: Nomination committed appointed for LeoVegas ahead of 2018 Annual General Meeting23.11.2017 11:50 | Pressmeddelande
In accordance with the principles for appointment of a nomination committee of LeoVegas AB (publ) ("the Company" or "LeoVegas") that were adopted by the Annual General Meeting on 17 May 2017, the Nomination Committee shall consist of four members appointed by the three largest shareholders as at 30 September 2017, together with the Chairman of the Board. Based on the above, the Nomination Committee ahead of the 2018 Annual General Meeting has been determined to consist of the following persons, who represent approximately 23% of the number of shares and votes in the Company as per 30 September 2017: Anders Fast, Nomination Committee chair, representing Gustaf Hagman Joachim Spetz, representing Swedbank Robur Fonder Dan-Alp Lindberg, representing Robin Ramm-Ericson Mårten Forste, Chairman of the Board The No
LeoVegas AB: Valberedning utsedd i LeoVegas inför årsstämma 201823.11.2017 11:50 | Pressmeddelande
Enligt de principer för valberedning i LeoVegas AB (publ) ("Bolaget" eller "LeoVegas") som antogs på årsstämman den 17 maj 2017 ska valberedningen bestå av fyra ledamöter utsedda av de tre största aktieägarna per den 30 september 2017, jämte styrelsens ordförande. Baserat på ovanstående har valberedningen inför årsstämman 2018 fastställts till att bestå av följande personer som tillsammans representerar cirka 23 procent av antalet aktier och röster i Bolaget per den 30 september 2017: Anders Fast, valberedningens ordförande och utsedd av Gustaf Hagman Joachim Spetz, utsedd av Swedbank Robur Fonder Dan-Alp Lindberg utsedd Robin Ramm-Ericson Mårten Forste, styrelseordförande Valberedningens förslag kommer att presenteras i kallelsen till årsstämman 2018 samt på bolagets hemsida, www.leovegasgroup.com.
Hemcheck Sweden AB: Viktigt patent beviljat av PRV23.11.2017 09:00 | Pressmeddelande
PRESSMEDDELANDE Viktigt patent beviljas av PRV PRV, det svenska patent och registreringsverket, meddelar att HemChecks patentansökan gällande bolagets blodseparationsteknik kommer att beviljas för Sverige den 19 december 2017. Patentets publiceringsnummer kommer att bli 539853. -För HemCheck är patentet strategiskt mycket viktigt, eftersom det innefattar vår teknik för blodseparation. Det skyddar den teknik som gör att en ej definierad blodvolym kan användas i vårt engångstest och det är just det som gör vårt hemolystest så unikt, enkelt och användarvänligt - och dessutom mycket snabbt. I kombination med övriga patent har vi nu ett mycket bra skydd för den metod som HemChecks affärsidé i grunden bygger på, säger vd Annelie Brolinson i en kommentar. En internationell patentansökan har lämnats in för att söka skydd på övriga viktiga marknader. För ytterligare information, kontakta: Hemcheck Sweden AB
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum